ReviewAnnals of hematology2026
ARAF mutated langerhans cell histiocytosis developed on the background of ARAF/JAK2 mutated polycythaemia vera: evidence of branching evolution from the same progenitor cell. A case report and literature review.
Review in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The case report presents the first documented instance of ARAF-mutated Langerhans cell histiocytosis (LCH) arising in a patient with ARAF/JAK2-mutated polycythaemia vera (PV), providing compelling evidence for a clonal relationship and branching evolution from a common progenitor precursor. The patient, a 63-year-old male, initially presented with classic PV symptoms and was diagnosed with JAK2 p.V617F mutated PV. Over the disease course, persistent monocytosis and progressive splenomegaly were noted, with subsequent development of a diffuse, non-itching maculopapular skin eruption in the setting of LCH. Histopathological and molecular analyses of bone marrow and skin lesions revealed the presence of ARAF, IDH2 and ASXL1 mutations in both tissues. This molecular profile supports the hypothesis of divergent evolution from a shared ARAF/IDH2/ASXL1-mutated clone, with subsequent acquisition of JAK2. Therapeutic management included phlebotomies, aspirin, hydroxyurea, peginterferon alfa-2a, and ruxolitinib, with variable responses and eventual disease progression. The patient ultimately succumbed to infectious complications. We further reviewed the literature on clonally related myeloproliferative neoplasms and LCH, highlighting the rarity of such cases and the potential role of chronic inflammation, monocytosis, and targeted therapies (e.g., JAK inhibitors) in disease evolution. The findings underscore the importance of comprehensive molecular profiling in patients with overlapping haematologic and histiocytic disorders and propose a model of branching evolution that may inform future research and therapeutic strategies. This first reported case expands the understanding of LCH ontogeny and its association with myeloid neoplasms, emphasizing the need for further studies on clonal haematopoiesis and lineage plasticity in these rare disease intersections.
Indexed as
Identifiers
42448959What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.